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Abstract (250; structured; max 250 words) 
Objective: The rising prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic 
steatohepatitis (NASH) presents many public health challenges, including a substantial impact on 
healthcare resource utilization and costs. There are important regional differences in the burden 
of NAFLD/NASH, and Spain-specific data are lacking. This retrospective, observational study 
examined the impact of liver disease severity, comorbidities, and demographics on healthcare 
resource utilization and costs in Spain. 
Methods: Patients enrolled in Spanish National Health System′s Hospital Discharge Records 
Database were categorized as incident NAFLD/NASH, NAFLD/NASH non-progressors, 
compensated cirrhosis (CC), decompensated cirrhosis (DCC), liver transplantation (LT), or 
hepatocellular carcinoma (HCC). Patients were followed for a 6-month post-index period for liver 
disease progression. Pre- and post-index healthcare resource utilization and costs per patient per 
month (PPPM) in 2017 Euro were calculated. 
Results: A total of 8,205 NAFLD/NASH patients (mean age 58.4; 54% males) were identified; 5,984 
(72.9%) were non-progressors, 2,028 (24.7%) progressed to DCC, 139 (1.7%) to CC, 115 (1.4%) to 
LT, and 61 (0.7%) to HCC. Pre-index comorbidity burden was high across cohorts, and the 
frequency of comorbidities increased with disease severity. Average length of stay (LOS) 
increased significantly (23% to 41%) from pre- to post-index, with significantly longer LOS in 
patients with more severe liver disease. All-cause PPPM costs increased significantly (44% to 
46%) from pre- to post-index, with higher costs evident for more severe disease. 
Conclusions: Progression of NAFLD/NASH was associated with significantly higher costs and 




Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease worldwide,1-5 
with disease severity ranging from simple steatosis to the combination of steatosis, 
inflammation, and hepatocyte ballooning that is characteristic of nonalcoholic steatohepatitis 
(NASH).6,7 NAFLD/NASH is widely recognized as the hepatic manifestation of metabolic 
syndrome,6,8,9 and affected patients at increased risk of insulin resistance and type 2 diabetes 
mellitus,7,10-13 hyperlipidemia,7,12-14 obesity,13,15,16 and hypertension.7,12,13,15,17 With the 
progression of NAFLD to NASH, patients are also at substantially greater risk of liver fibrosis and 
cirrhosis,7,13,15,18 hepatocellular carcinoma (HCC),4,7,13,15,18,19 liver transplantation (LT),20,21 and 
death.7,13,22,23 
The prevalence of NAFLD/NASH is projected to increase worldwide as obesity and diabetes rates 
continue to rise and the population of the world ages, with current estimates suggesting that 
25% of the global adult population has NAFLD, and 3% to 5% are affected by NASH.3,24 A dynamic 
Markov model, based on data from national reports and surveillance activities combined with a 
literature review and consultation with experts, characterized trends in NAFLD prevalence and 
progression in eight countries including China, France, Germany, Italy, Japan, Spain, the United 
Kingdom (UK), and the United States (US). By 2030, the NAFLD population is projected to increase 
worldwide by 18.3% to 100.9 million cases, with a 15% to 56% increase in the worldwide 
prevalence of NASH. Within Europe, the highest prevalence of NAFLD is predicted for Italy at 
29.5%, and the highest prevalence of NASH is estimated for Spain at 29.5%.1 
As the prevalence of NAFLD and NASH rises, the associated health, economic, and personal 
impacts on patients, family members, society, and healthcare delivery systems are expected to 
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increase substantially.5,25-28 NALFD/NASH has a significant and negative impact on patients’ 
quality of life and wellbeing.28-32 Affected patients also experience higher rates of depression 
than patients with hepatitis B and the general population,33 and are at increased lifetime risk of 
major depressive disorder.34 
NAFLD/NASH also imposes a substantial burden on healthcare resource utilization and 
costs.5,26,27,35,36 Annual direct medical costs for all incident and prevalent cases of NAFLD were 
estimated at €35 billion in 2016 for Germany, France, Italy, and the UK, with societal costs ranging 
from €31 billion in the UK to €75.7 billion in France.27 Healthcare resource utilization and costs 
are significantly higher for patients who progress to more severe liver disease compared with 
NAFLD/NASH and no progression.25,37 The impact of NAFLD/NASH on healthcare systems and 
direct costs is projected to increase5,36 as the number of affected persons rises in Europe and 
worldwide. 
Accurate estimates of the prevalence and burden of NAFLD/NASH are required for the design, 
implementation, and evaluation of a strategic public health response to address the growing 
impact of NAFLD/NASH in specific countries and regions of the world.5,38,39 It is well-recognized 
that the burden of NAFLD/NASH is diverse, with variations in the epidemiology of disease as well 
as risk factors associated with disease development and progression.39 Modeling approaches 
provide useful information about variations between countries and regions, but are subject to a 
number of limitations including inconsistencies in clinical assessment of steatosis, variability in 
case definitions, incomplete data, use of older data that may not accurately represent current 
patterns and trends, differences in diagnostic and staging techniques, and small sample sizes.1,7 
Real-world, population-based data can more accurately characterize the prevalence, 
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progression, and economic impact of NAFLD and NASH within specific countries and regions, 
which, in turn, can inform health policy.40 A cross-sectional study reported an overall prevalence 
for NAFLD of 25.8% in adult patients receiving treatment at primary care centers in Catalonia, 
Spain, ranging from 20.3% in women to 33.4% in men. [Caballería 2010] Important limitations of 
this study were a 60% nonparticipation rate and reliance on echography for the diagnosis of 
NAFLD. 
We performed this study to characterize the current prevalence of NAFLD/NASH and identify 
factors associated with disease progression and health care burden in NAFLD/NASH patients with 
and without advanced liver disease in Spain. The specific study objectives were to evaluate the 
impact of severity of liver disease, demographic characteristics, and comorbid health conditions 
on healthcare resource utilization and costs in a large real-world cohort of NAFLD/NASH patients 
in Spain. 
Methods 
Design and data source 
We performed a longitudinal, retrospective cohort study using data from Spanish National Health 
System′s Hospital Discharge Records Database (Conjunto Mínimo Básico de Datos or CMBD) for 
the period 01 January 2006 through 30 April 2017. Under the supervision of the Spanish Ministry 
of Health, the CMBD compiles information from 192 private and 313 public hospitals in all regions 
of Spain. The database contains patient-level information on demographic characteristics, 
primary and secondary diagnoses, readmissions, health care costs, dates of admission and 
6 
 
discharge, and mean length of stay for hospitalized patients. Information for this study was 
available for more than 36 million patients between 2006 and 2017. 
Patient-level data were anonymized in accordance with the principles of Good Clinical Practice 
and the Declaration of Helsinki. According to Spanish data protection regulations, patient consent 
and approval by an institutional review board or ethics committee were not required for de-
identified patient information. 
Sample selection 
Patients eligible for inclusion in this analysis were ≥18 years with at least one inpatient claim 
between January 1, 2006 and April 30, 2017 for a known diagnosis of NAFLD or NASH. A diagnosis 
of NAFLD or NASH was based on the International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM) codes 571.8 and 571.9 and the International Classification of 
Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes K76.0, K75.81. ICD-10-CM 
codes were first implemented in Spain in January 2016, and this study includes a time period that 
preceded and followed the implementation of ICD-10-CM codes. Therefore, both ICD-9-CM and 
ICD-10-CM diagnosis codes for NAFLD and NASH were utilized. 
Patients were excluded if, at any time during the study period, they were diagnosed with HIV, 
viral hepatitis B or C, autoimmune hepatitis, any other viral hepatitis, personal history of 
alcoholism, alcohol dependence, alcoholic liver diseases, toxic liver disease, Wilson’s disease, 
Gaucher’s disease, lysosomal acid lipase deficiency, biliary cirrhosis, cholangitis, and 
hemochromatosis. The complete list of ICD-9-CM and ICD-10-CM codes for NAFLD/NASH, CC, 




Eligible patients were required to have continuous medical and prescription coverage for at least 
6 months before and at least 1 month following the NAFLD/NASH index date. The date of the first 
claim associated with the diagnosis of NAFLD/NASH was defined as the index date. The baseline 
or pre-index period was defined as the 6-month interval immediately preceding the index date. 
The follow-up period for eligible patients was defined as the time from the index date to one of 
the following, whichever was earliest: 1) progression to a different disease severity cohort, 2) 6 
months after the index date, 3) end of coverage, 4) death, or 5) end of the study period. 
The presence of ICD-9-CM or ICD-10-CM codes for progressive liver disease following the index 
date resulted in the categorization of patients into one of six non-mutually exclusive cohorts 
based on the severity of liver disease. The cohorts were incident NAFLD/NASH overall, 
NAFLD/NASH non-progressors, CC, DCC, LT, and HCC (Figure 1). 
Endpoints 
Patient age, sex, and region of residence as well as comorbid health conditions were 
characterized for the pre-index period for each of the disease severity cohorts. ICD-9-CM and 
ICD-10-CM codes were used to identify comorbidities, which included abdominal pain, anemia, 
bariatric surgery, cardiovascular disease (CVD), diabetes mellitus (type 1 and type 2), dyspepsia, 
hyperlipidemia, hypertension, insomnia, obesity, renal impairment, sleep apnea, thyroid disease, 
and vitamin D deficiency.  
The primary endpoints were all-cause healthcare resource utilization and costs for the pre-index 
and post-index periods for each of the disease severity cohorts. Health care costs were expressed 
as per patient per month (PPPM) values and included outpatient, inpatient, and pharmacy 
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expenditures. Costs were adjusted to 2017 EUR. Measures of healthcare resource utilization 
included the number of readmissions per patient and average length of stay (LOS) per admission. 
Statistical analysis 
Descriptive statistics were calculated for all variables, including frequencies and percent 
responses for categorical variables and mean, median, and standard deviation (SD) for 
continuous variables. Resource utilization and costs were analyzed as continuous variables. 
Chi-squared tests were used for the analysis of differences in categorical variables, and paired t-
tests were used for comparisons of pre- and post-index healthcare resource utilizations and 
costs. P-values <0.05 were considered significant. Generalized linear models (GLM) with gamma 
error distribution and log-link function evaluated the incremental cost and resource utilization 
burden after adjustment for severity of liver disease and pre-index demographic and clinical 
characteristics. An important advantage of the GLM approach is that the log-transformed model 
is not subject to the assumptions that are necessary for a least-squares regression model, which 
are usually not held with cost data. For categorical variables, GLM estimates can be interpreted 
as percentage changes in cost. Explanatory variables included severity of liver disease, age, sex, 
geographic region, and comorbid conditions. All statistical analysis was performed with SAS 
version 9.4 [SAS institute, Cary, NC]. 
Results 
The CMBD database included 36,856,032 patients for the period of January 1, 2006 through April 
30, 2017, with 13,988 (0.04%) patients diagnosed with NAFLD/NASH (Figure 2). After applying 
the inclusion and exclusion criteria, 8,205 patients were eligible for inclusion in this analysis. Of 
these, 5,984 (72.9%) did not progress to a more advanced stage of liver disease and were 
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categorized as NAFLD/NASH non-progressors. A diagnosis of CC was confirmed in 139 (1.7%) 
patients, 2,028 (24.7%) were diagnosed with DCC, 115 (1.4%) had LT, and 61 (0.7%) progressed 
to HCC. Among patients diagnosed with cirrhosis (CC or DCC), 93.4% had a decompensated event 
at the time of their initial diagnosis of cirrhosis. 
Demographic and clinical characteristics 
The overall mean patient age was 58.4 years, ranging from 54.3 years for patients in the LT group 
to 70.9 years for those with HCC (Table 1). The majority of patients were male at 53.8% of all 
NAFLD/NASH patients, ranging from 52.2% of NAFLD/NASH non-progressors to 65.6% of those 
diagnosed with HCC.  
Baseline rates of comorbid health conditions were high overall and in each of the disease severity 
cohorts. The most common comorbidities were hypertension, type 2 diabetes, and 
hyperlipidemia. The prevalence of comorbid health conditions was higher in patients with more 
advanced liver disease compared with those in the NAFLD/NASH non-progressors group. 
Similarly, the frequency of multiple comorbidities increased significantly as patients progressed 
to more severe liver disease (all P<0.05). 
Healthcare resource utilization 
The mean number of admissions was numerically greater during the pre- and post-index periods 
for patients with CC, DCC, LT, and HCC compared to those in the NAFLD/NASH no-progressors 
group. There were no significant changes in the mean number of hospital readmissions during 




The shortest mean LOS per admission at baseline was 4.13 days for patients with NAFLD/NASH 
and no progression. Baseline LOS was significantly higher in each of the disease severity cohorts 
compared with NAFLD/NASH non-progressors at 8.11 days for CC patients, 10.74 days for DCC, 
days 6.12 for LT, and 9.08 days for HCC (Figure 2). There was a numerical increase in mean LOS 
from baseline to the post-index period at 5.74 days for NAFLD/NASH non-progressors, although 
this was not statistically significant. Mean LOS during the follow-up period was significantly 
higher from baseline within each of the disease severity cohorts, increasing to 9.98 days for those 
with CC, 13.86 days for DCC, 8.01 days for LT, and 11.99 days for patients with HCC. 
Healthcare costs 
Mean PPPM health care costs for the pre-index period were significantly lower for patients with 
NAFLD/NASH and no further progression compared to those with more severe liver disease 
(P<0.05 for all comparisons) (Figure 3). There was a significant increase in PPPM costs during the 
post-index period within each of the disease severity groups (all P<0.05). In addition, the increase 
in costs was significantly greater for patients with more severe liver disease compared to those 
with no evidence of progression (P<0.05 for all comparisons). Post-index total PPPM mean 
expenditures were also significantly higher for patients with DCC, LT, and HCC compared to those 
with CC (all P<0.05). 
Within each disease severity cohort, higher costs from the pre-index to post-index periods were 
primarily associated with inpatient expenditures, which increased with the severity of liver 
disease. Inpatient PPPM costs during the post-index period accounted for 42% of the overall 
increase in health care expenditures for NAFLD/NASH non-progressors, 55% for those with CC, 
and 45% in the DCC, LT, and HCC cohorts. Significant predictors of higher, post-index health care 
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costs were patient age and selected comorbid health conditions including renal impairment, 
sleep apnea, anemia, CVD, and tobacco use (Table 3). After adjusting for severity of liver disease, 
as compared to NAFLD/NASH non-progressors (adjusted costs: €4,422), the cost of CC, DCC, LT 
and HCC was 1.13, 1.40, 2.37 and 1.55 times higher respectively, with  adjusted costs being 
€5,014, €6,191, €10,501, and €6,869 respectively (p<0.001)(Figure 4).  
Discussion 
This real-world analysis of hospital data for patients with NAFLD/NASH confirms the substantial 
impact of NAFLD/NASH on healthcare systems in Spain. Hospital LOS for both the pre- and post-
index periods was significantly longer for patients who progressed to more severe liver disease 
compared to those with NAFLD/NASH and no further progression. Expenditures during the pre-
index period were significantly lower for the NAFLD/NASH non-progressors group compared to 
costs in patients with CC, DCC, LT, and HCC. Similarly, post-index PPPM costs within each of the 
disease severity groups were significantly higher than those for patients who experienced no 
disease progression. The primary driver of cost increases from baseline to the post-index period 
were inpatient services, which accounted for 45% to 55% of the increase in expenditures for CC, 
DCC, LT, and HCC patients. Total costs for patients with more severe liver disease remained higher 
compared with patients without progression after adjusting for demographic and clinical 
characteristics. 
The study findings are consistent with previous researches that report a substantial impact of 
NAFLD/NASH on healthcare resource utilization and costs, particularly for patients with more 
severe liver disease.1,3,5,25-27,37,41 A recent analysis of commercially insured patients in the US 
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reported a 41% increase in the number of inpatient hospital admissions and a 61% increase in 
the mean number of admissions following a diagnosis of CC. Per patient per year mean total 
health care costs rose from $25,738 (pre-diagnosis) to $36,558 (post-post-diagnosis).41 Similarly, 
a retrospective cohort analysis of NAFLD/NASH patients enrolled in Medicare studies reported 
higher inpatient and outpatient charges for CC and DCC patients compared with noncirrhotic 
NAFLD patients. Compared with CC patients, those with DCC had higher total inpatient and 
outpatient charges.26 
However, many of these analyses are specific to the US26,37,42 and most estimates of the economic 
impact of NAFLD/NASH in Europe and other countries have been generated by predictive 
models.1,3,5,13,27 While informative, there are important limitations in the methodologies used to 
generate these estimates, including variability in the methods used to ascertain a clinical 
diagnosis of NAFLD and NASH; use of older data that may not accurately represent current 
patterns and trends in factors such as rates of obesity and diabetes; lack of consistency in 
techniques, terminology, and classification systems for fibrosis and cirrhosis stage; inclusion of 
data from studies that relied on small sample sizes or had short follow-up durations; and 
between-study variations in study aims and population characteristics.1,7 This real-world analysis 
provides a current and more accurate perspective on patterns of healthcare resource utilization 
and direct medical costs that are associated with NAFLD/NASH in Spain. Such information can be 
used to guide the development of interventions to improve the management of patients with 




This analysis also attempted to highlight the prevalence and impact of comorbidities in 
NALFD/NASH by severity of liver disease. Across the liver disease cohorts, we found that 15% to 
45% of patients had at least one comorbid condition and the frequency of comorbid health 
conditions increased as patients progressed from incident NAFLD/NASH to more severe liver 
disease. Previous studies also report an association of NAFLD/NASH and various comorbidities 
such as CVD,8,26 obesity, insulin resistance, type 2 diabetes, hypertension, and hyperlipidemia, 
with each of these disorders characteristic of the metabolic syndrome.6,8-11,14,16,17,43,44 In this 
Spanish population, we found that renal impairment, anemia, sleep apnea, and smoking were 
also associated with increased severity of liver disease and may have contributed to the higher 
costs and service utilization observed in these patients. Ongoing monitoring and management of 
all comorbid health conditions, including those that might be more typical of patients receiving 
care in Spain, may allow public health approaches to be targeted to the specific risk profile of 
patients in the Spanish healthcare system and may optimize the use of health care resources and 
budgets. 
As the prevalence of NAFLD/NASH and associated comorbidities continues to increase 
worldwide, the need for public health interventions and initiatives that are tailored to the unique 
demographic and clinical characteristics of patients residing in diverse regions of the world will 
be of critical importance.6,7,45 Such an approach will rely on improvements in the identification of 
patients with progressive disease in the absence of symptoms, initiation of pharmacological and 
lifestyle interventions to address the metabolic and cardiovascular comorbidities that are 
characteristic of NAFLD/NASH, and promotion of the recommended lifestyle interventions to 
prevent or slow disease progression. Optimal clinical management combined with efforts to 
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reduce and manage risk factors for mortality and disease progression have the potential to 
decrease healthcare resource utilization and costs, especially when considered over the duration 
of disease. Such efforts are particularly important in the absence of noninvasive screening and 
diagnostic tests for NAFLD and approved pharmacotherapies for the treatment of NAFLD/NASH. 
Consideration of regional and between-country variations in demographics, geography, and 
historical factors will be essential when planning a comprehensive program for Spain to address 
the current and future impact of NAFLD/NASH. An accurate understanding of the epidemiologic 
burden of NAFLD/NASH, including changes over time and factors that may be associated with 
poor clinical outcomes or greater need for healthcare resources will form the basis of a strong 
NAFLD/NASH public health initiative in Spain with the potential to reduce the future burden of 
NAFLD/NASH.39 
The retrospective study design and use of a hospital discharge records database, which relies on 
administrative claims data for disease identification and assessment, are two important 
limitations of this analysis. Data for the CMBD are primarily collected for accounting purposes, 
and the information is subject to data coding limitations, data entry errors, and misclassification 
of NAFLD/NASH and liver disease severity. In addition, the CMBD may not be fully representative 
of the entire population of Spain, and the patterns of healthcare resource utilization and costs in 
this study may not apply to the general population of Spanish patients with NAFLD/NASH who 
are not included in the CMBD. 
The identification of patients with advanced liver disease was limited to ICD-CM-09 and ICD-CM-
10 codes rather than laboratory or biopsy data or other measures of fibrosis such as elastography 
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and ultrasound. This may have resulted in an underestimation of the true number of patients 
who experienced disease progression in the case of asymptomatic disease progression. Patients 
could have had more severe disease before their initial NASH/NAFLD diagnosis, and the incident 
NAFLD/NASH non-progressor group might have included F0-F3 patients as well as undiagnosed 
F4 (CC) patients due to under-coding and lack of ICD codes for F0-F3. Moreover, since CMBD 
includes hospitalized patients in Spain, the estimates reported here for severe liver diseases 
could have be inflated due to patients being comparatively sicker. Finally, several potentially 
important factors were controlled for in these multivariable analyses, but adjustment was limited 
to characteristics that could be measured with data that were available. 
While these are important limitations, this study has several strengths. The analysis was based 
on a large cohort of NAFLD/NASH patients at varying stages of disease severity. The study tracked 
patients’ progression or non-progression through CC, DCC, LT, and HCC.  The inclusion criteria 
required patients to have at least one-month follow-up after the post-index date. This criterion 
preserved sample size and may have reduced bias associated with a longer follow-up interval in 
healthier patients who did not die or progress to a more advanced stage of liver disease. 
In conclusion, patients with more severe liver disease were more likely to experience one or more 
comorbid health conditions, use more health care resources and incur higher costs compared to 
those with no evidence of disease progression. The primary cost drivers were associated with 
inpatient services. These findings highlight opportunities to improve overall patient management 
and ensure optimal allocation of healthcare resources and control costs associated with 








The analyses were performed in collaboration with Spain’s National Health System′s Hospital Discharge 
Records Database (CMBD). Carole Alison Chrvala, PhD, Health Matters, Inc., is acknowledged for her 








Figure 1. Patient disposition 
Group Patients, n 
All patients in the Spanish hospitalization database with at least one day of enrollment 
from 01/01/2006 to 04/30/2017 
36,856,032 
All patients with ≥1 ICD-10-GM code for NAFLD/NASH from 01/01/2006 to 04/30/2017 
[date of first diagnosis is the index date] 
13,988 
All patients with ≥1 ICD-10-GM code for NAFLD/NASH from 01/01/2006 to 04/30/2017 
and no diagnosis of NAFLD/NASH from 01/01/2005 to 01/01/2006: incident 
NAFLD/NASH 
12,022 
Continuous enrollment with medical and pharmacy benefits for ≥6 months before the 
index date: pre-index period 
11,908 
Continuous enrollment with medical and pharmacy benefits for ≥1 month after the index 
date: post-index period 
11,785 
Adult patients (≥18 years of age) at the time of the index date 11,434 










• No evidence of NAFLD/NASH 1 
year before NAFLD/NASH index 
date 
• Continuous enrollment for ≥1 
year before and after diagnosis 
of NAFLD/NASH 
• No evidence of progression to 
CC, DCC, LT, or HCC after 
NAFLD/NASH index date 
• Continuous enrollment for ≥1 
year before and after diagnosis 
of NAFLD/NASH 
 
• ≥1 ICD-10-GM/OPS/DRG code for progressive 
liver disease before NAFLD/NASH index date 
• Continuous enrollment for ≥1 year before 
















Figure 2. Pre- and post-index average length of stay per admission by severity of liver disease 
 
 
All comparisons with NAFLD/NASH non-progressors or CC were statistically significant (P<0.05). 
GLM model adjusted for age, sex, region, and comorbid health conditions (abdominal pain, anemia, 
apnea, bariatric surgery, cardiovascular disease, type 2 diabetes, dyspepsia, hyperlipidemia, 





































CC, compensated cirrhosis; DCC, decompensated cirrhosis; HCC, hepatocellular carcinoma; 











Figure 4. Multivariable adjusted per patient per month all-cause health care costs by severity of 
liver disease: Post-index period 
 
CC, compensated cirrhosis; DCC, decompensated cirrhosis; HCC, hepatocellular carcinoma; 








Table 1. Baseline demographic and clinical characteristics  




































































































































Comorbid Health Conditions  
Abdominal pain 178 (2.2) 158 (2.6) 0 (0.0)* 19 (0.9)*† 1 (0.9)* 0 (0.0)* 
Anemia 984 (12.0) 367 (6.1) 33 (23.7)*† 597 (29.4)*† 7 (6.1)*† 16 (26.2)*† 
Apnea 123 (1.5) 92 (1.5) 1 (0.7)* 31 (1.5)* 0 (0.0)* 1 (1.6)* 
Bariatric surgery 1 (0.0) 1 (0.02) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Cardiovascular disease 726 (8.8) 365 (6.1) 13 (9.4)* 353 (17.4)*† 1 (0.9)*† 5 (8.2)*† 
Diabetes mellitus, type 
1 
39 (0.5) 32 (0.5) 1 (0.7)* 7 (0.4)* 0 (0.0)* 0 (0.0)* 
Diabetes mellitus, type 
2 
1,656 (20.2) 965 (16.1) 37 (26.6)* 657 (32.4)*† 17 (14.8)*† 19 (31.1)*† 
Dyspepsia 208 (2.5) 130 (2.2) 5 (3.6)* 74 (3.7)*† 1 (0.9)* 1 (1.6)* 
Hyperlipidemia 1,204 (14.7) 932 (15.6) 16 (11.5)* 258 (12.7)*† 2 (1.7)*† 6 (9.8)*† 
Hypertension 2,299 (28.0) 1,476 (24.7) 45 (32.4)* 776 (38.3)*† 19 (16.5)*† 24 (39.3)*† 
Insomnia 8 (0.1) 4 (0.07) 0 (0.0) 4 (0.2) 0 (0.0) 0 (0.0) 
Obesity 569 (6.9) 424 (7.1) 12 (8.6)* 136 (6.7)*† 5 (4.4)*† 0 (0.0)*† 
Renal impairment 643 (7.8) 252 (4.2) 16 (11.5)* 376 (18.5) † 11 (9.6)* 10 (16.4)* 
Smoking 963 (11.7) 677 (11.3) 18 (12.9)* 267 (13.2)*† 7 (6.1)*† 6 (9.8)*† 
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Thyroid disease 491 (6.0) 331 (5.5) 12 (8.6)* 151 (7.5)*† 3 (2.6)*† 3 (4.9)*† 
Vitamin D deficiency 32 (0.4) 26 (0.4) 0 (0.0)* 6 (0.3)* 0 (0.0)* 0 (0.0)* 
Multiple Comorbid Health Conditions  
CVD AND diabetes 
(type 1 or 2) AND renal 
disease 
236 (2.9) 50 (0.8) 4 (2.9)* 62 (3.1)*† 0 (0.0)* 3 (4.9)* 
CVD OR diabetes (type 
1 or 2) OR renal disease 
1,727 (21.0) 1,034 (17.3) 35 (25.2)* 690 (34.1)*† 16 (13.9)*† 16 (26.2)*† 
At least 1 of 5 
comorbidities¶ 
3,648 (44.5) 1,190 (19.9) 33 (23.7)* 738 (36.4)*† 17 (14.8)*† 18 (29.5)*† 
At least 2 of 5 
comorbidities¶ 
1,959 (23.9) 454 (7.6) 14 (10.1)* 319 (15.7)*† 3 (2.6)*† 9 (14.8)* 
At least 3 of 5 
comorbidities¶ 
782 (9.5) 108 (1.8) 4 (2.9)* 101 (5.0)*† 0 (0.0)* 3 (4.9)* 
Baseline period defined as 6 months preceding the index date. ¶CVD, diabetes, hyperlipidemia, hypertension, renal disease. *P<0.05 
for comparison with NAFLD/NASH non-progressors. †P<0.05 for comparison with CC. 
CC, compensated cirrhosis; CVD, cardiovascular disease; DCC, decompensated cirrhosis; HCC, hepatocellular carcinoma; LT, liver 
transplantation; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; SD, standard deviation. 
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Table 2. Multivariate adjusted model for per patient per month total cost 























































































Diabetes mellitus, type 1 
Diabetes mellitus, type 2 


































































*Baseline period defined as 6 months preceding the index date. †Reference: patients from other 
regions. #Reference: patients without comorbidity. 
CC, compensated cirrhosis; CI, confidence interval; CVD, cardiovascular disease; DCC, 
decompensated cirrhosis; HCC, hepatocellular carcinoma; LT, liver transplantation; NN, 
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